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Summary 
The delivery of therapeutic agents is characterised by numerous challenges 
including poor absorption, low penetration in target tissues and unspecific 
dissemination in organs, leading to toxicity or poor drug exposure. Several 
nanomedicine strategies have emerged as an advanced approach to enhance drug 
delivery and improve the treatment of several diseases. Numerous processes 
mediate the pharmacokinetics of nanoformulations, with the absorption, distribution, 
metabolism and elimination (ADME) being poorly understood and often differing 
substantially from traditional formulations..Understanding how nanoformulation 
composition and physicochemistry influences drug distribution in the human body is 
of central importance when developing future treatment strategies. A helpful 
pharmacological tool to simulate the distribution of nanoformulations is represented 
by physiologically based pharmacokinetics (PBPK) modelling, which integrates 
system data describing a population of interest with in vitro nanoformulation data 
through a mathematical description of ADME. The integration of property–distribution 
relationships in PBPK models may benefit nanomedicine research, giving 
opportunities for innovative development of nanotechnologies. This approach will not 
only improve our understanding of the mechanisms underpinning nanoformulation 
disposition and allow for more rapid and accurate determination of their kinetics, but 
will also help clarify interactions between different nanoformulation properties, 
identifying antagonistic or synergistic effects. Consequently, the design and 
development of nanoformulations can be informed by this modelling approach to 
generate novel nanoformulations with desirable pharmacokinetics. 
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Perspectives and opportunities in nanotechnology for drug delivery  
Acceptable pharmacokinetics of drugs can be impeded by several factors, including 
poor absorption, low penetration into target tissues and high clearance. Insolubility of 
drugs, with the resulting low bioavailability, remains a serious concern for drug 
development programs in the pharmaceutical industry. It is estimated that >60% of 
new drug candidates are poorly soluble in water, inhibiting development programmes 
and ultimately the success of new treatments (Sareen et al., 2012; Sikarra et al., 
2012 ). Moreover, the lack of drug penetration in tissues where exposure is most 
needed can have a detrimental influence on therapy efficacy and toxicity. 
Numerous nanomedicine strategies are currently being assessed to improve drug 
delivery. Nanomedicines include nanoparticles (defined as solid submicron particles 
consisting of polymers or inorganic material) and liquid based drug nanocarriers 
such as nanoemulsions. Nanoformulations can be produced to contain a drug (or 
drugs) which may be associated with the particle in various ways (Kreuter, 1994). 
Many nanoformulations can effectively be absorbed and subsequently concentrated 
in tissues through passive targeting, exploiting both the physicochemical 
characteristics of the nanocarriers and the specific properties of the tissues of 
interest. Different strategies can also be applied for active targeting of tissues, 
pathogens and cancer cells.  
The wide variety of nanocarrier designs means that a large, almost overwhelming, 
range of delivery strategies are available for research and application. Polymers can 
be used as containers for drug molecules, either by forming solid polymer matrix 
nanoparticles to encapsulate drugs, or through the construction of vehicles such as 
block copolymer liposomes/vesicles, micelles and nanoemulsions (Wischke and 
Schwendeman, 2008). Direct non-covalent or covalent conjugation of drugs to 
polymers have been successfully used to enhance circulatory times and deliver 
drugs through triggered/controlled release (Joralemon et al., 2010). A wide variety of 
inorganic oxides have been used to create nanoparticles, such as gold (Thakor et 
al., 2011), silver (Ong et al., 2013; Zhang et al., 2013), silica (Wu et al., 2013) and 
iron (Ittrich et al., 2013). However, the influence that these formulations can have on 
drug pharmacokinetics is only partly understood. In this review we describe what is 
known of the main processes regulating nanoformulation ADME. We also discuss 
strategies to optimise the design of nanoformulations, focussing on the use of 
mechanistically-based ADME modelling to obtain optimal pharmacokinetics. 
  
Importance of nanoformulation pharmacokinetics 
The use of nanoformulation delivery systems has the potential to radically improve 
drug pharmacokinetics. However, efficacy and toxicity of drugs can also be 
negatively influenced by nanoformulation distribution: insufficient absorption and 
diffusion into tissues may compromise drug activity, while excessive nanoformulation 
accumulation could lead to tissue-specific toxicity (related to the drug, the 
nanoformulation, or potentially both). Consequently, understanding the interactions 
between nanoformulations and the human body is of central relevance for the 
engineering of future treatment strategies, and a thorough investigation of the 
processes regulating nanoformulation disposition is essential to optimise effective 
and safe nanoformulations for drug delivery. Several processes mediate the 
distribution of nanoformulations in the human body and the absorption, distribution, 
metabolism and elimination of nanoformulations can differ substantially from 
traditional formulations. In most cases nanoformulation ADME is not fully 
characterised and can vary based on the characteristics of the nanoformulations 
(Figure 1). The preferred routes of administration for nanoformulations are oral, 




Certain nanoformulations can enhance the absorption of drugs by releasing drug into 
the lumen in a controlled manner, thus reducing solubility issues. The intestinal wall 
is designed to absorb nutrients and to act as a barrier to pathogens and 
macromolecules. Small amphipathic and lypholic molecules can be absorbed by 
partitioning into the lipid bilayers and crossing the intestinal epithelial cells by passive 
diffusion, while nanoformulation absorption may be more complicated due to the 
intrinsic nature of the intestinal wall. The first physical obstacle to nanoparticle oral 
absorption is the mucous barrier which covers the luminal surface of the intestine 
and colon (Corazziari, 2009; Johansson et al., 2011). The mucus barrier contains 
distinct layers and is composed mainly of heavily glycosylated proteins called 
mucins, which have the potential to block the absorption of certain nanoformulations. 
Modifications can be made to produce nanoformulations with increased mucous-
penetrating properties (Ensign et al., 2012). Once the mucous coating has been 
traversed, the transport of nanoformulations across intestinal epithelial cells can be 
regulated by several steps, including cell surface binding, endocytosis, intracellular 
trafficking and exocytosis, resulting in transcytosis (transport across the interior of a 
cell) with the potential involvement of multiple subcellular structures. Moreover, 
nanoformulations may also travel between cells through opened tight junctions, 
defined as paracytosis (Tuma and Hubbard, 2003). Non-phagocytic pathways, which 
involve clathrin and caveolae mediated endocytosis and macropinocytosis, are the 
most common mechanisms of nanoformulation absorption by the oral route, although 
heterogeneity in the efficiency of these processes has been described for different 
types of nanoformulations. Consequently, it is difficult to identify a predominant 
process determining transcytosis of nanoformulations (He et al., 2013; Hillaireau and 
Couvreur, 2009; Smith et al., 2012). 
 
Alternative administration routes 
The inability of certain nanoformulations to undergo efficient oral absorption 
necessitates alternative administration routes. Also, the use of non-oral 
administrations can provide additional benefits, such as direct targeting to the 
desired site of action (Patel et al., 2012) and an extended period of drug action (van 
't Klooster et al., 2010). 
The skin provides a desirable route of nanoformulation administration, as it avoids 
the risks associated with intravenous therapy and the inconveniences associated 
with varying gastric pH, emptying time, and first-pass hepatic metabolism. However, 
administration of drugs is not easy because of the impermeable nature of the skin 
(Menon et al., 2012; Rehman and Zulfakar, 2013). Transdermal administration has 
been optimised for nanoformulations such as SLNs and NEs, which are 
characterised by good biocompatibility, lower cytotoxicity and desirable drug release 
modulation (Cappel and Kreuter, 1991; Gide et al., 2013; Khurana et al., 2013). 
Topical ocular drug delivery provides a useful administration route for nanomedicines 
treating ocular pathologies, but utilisation is disadvantaged by the multiple defensive 
barriers of the eye (de Salamanca et al., 2006). Corneal and conjunctival epithelial 
cells are connected by intercellular tight junction complexes that limit the entrance of 
exogenous substances. In addition, the tear film can trap drugs and 
nanoformulations, removing them via the lacrimal drainage system. Consequently an 
efficient ocular drug delivery system has to interact with the ocular mucosa, protect 
the drug from chemical or enzymatic degradation and allow drug delivery to the 
ocular tissue. Different nanotechnologies have been utilised to overcome these 
barriers, helping the drug reach and target conjunctival epithelial cells (Alonso and 
Sánchez, 2004). Successful administration of nanoformulated intra-ocular-pressure-
lowering drugs (Chen et al., 2010; Hathout et al., 2007) and anti-apoptotic drugs 
(Nkansah et al., 2008) has been achieved in vivo. In addition, intravitreal 
administration of nanoformulations has been used to overcome absorption issues 
(Jiang et al., 2007). 
Nasal administration of certain nanoformulations has been assessed, hypothesising 
that nanoformulations may penetrate the nasal mucosal membrane. 
Nanoformulations can cross the membrane using a transmucosal route by 
endocytosis or via a carrier- or receptor-mediated transport process (Illum, 2007). 
Proof-of-concept has been achieved in vivo, for example by nasal administration of 
chitosan nanoparticles of tizanidine to increase brain penetration and drug efficacy in 
mice (Patel et al., 2012). 
The lungs are a promising route of administration for drug delivery due to the large 
surface area, ease of access and the thinness of the air-blood barrier. The lumen of 
the bronchial airways is lined with a thin layer of serous ﬂuid, upon which ﬂoats a 
layer of mucus which helps to entrap aerosolized particles. The action of the cilia, 
present on the ciliated columnar epithelium, mediates the movement of the mucous 
layer towards the proximal airways, where it can be eliminated. The mucus barrier, 
metabolic enzymes in the tracheobroncial region and macrophages in the alveoli are 
the main barriers for penetration of drugs. Particle size is a major factor determining 
the diffusion of nanoformulation in the bronchial tree, with particles in the nano-sized 
region more likely to reach the alveolar region and particles with diameters between 
1 and 5 µm expected to deposit in the bronchioles (Musante et al., 2002; Patton and 
Byron, 2007). A limit to absorption has been shown for larger particles, presumably 
due to an inability to cross the air-blood barrier (Ryan et al., 2013b). Particles can 
gradually release the drug which can consequently penetrate into the blood stream, 
or alternatively particles can be phagocyted by alveolar macrophages (Bailey and 
Berkland, 2009).  
Certain nanoformulations have a minimal penetration through biological membranes 
in sites of absorption, therefore to obtain an efficient distribution in tissue an 
intravenous administration can be the preferred route (Wacker, 2013). Although 
long-term drug exposure has been demonstrated in certain cases (van 't Klooster et 
al., 2010), the use of intravenous injection for multiple short-acting treatments is 
limited due to inconvenience and safety issues. 
 
Distribution in tissues and organs 
Once a drug-containing nanoformulation has entered the systemic circulation, the 
subsequent distribution into tissues can begin. The distribution of nanoformulations 
can vary widely depending on the delivery system used, the characteristics of the 
nanoformulation, and potentially the variability between individuals (organ size, body-
fat index, etc). Another important factor to understand is the rate of drug loss from 
the nanoformulations, as the distribution characteristics of both the free drug and 
nanoformulated drug will most likely differ greatly. The main function of certain types 
of nanoparticles, for example SDNs, is the improvement of drug absorption, which 
does not require them to arrive intact in the systemic circulation. Consequently, the 
distribution and the clearance of these drugs would not be altered. Other 
nanotechnologies, however, are capable of surviving the absorption process, 
therefore altering the distribution and clearance of the contained drug. 
On reaching the systemic circulation, nanoformulations come into contact with 
numerous proteins which can give rise to the formation of dynamic nanoformulation-
protein coronas (Tenzer et al., 2013b). The protein corona influences 
nanoformulation size and physicochemical characteristics, consequently affecting 
processes such as nanoformulation degredation, cellular uptake (Paula et al., 2013), 
accumulation and clearance (Peng et al., 2013). Nanoformulation-protein coronas 
can also influence the body, potentially causing pathologies such as inflammation 
(Saptarshi et al., 2013) and haemolysis (Tenzer et al., 2013a). Proteins can adhere 
to nanoformulations through forces such as Van der Waals interactions, hydrogen 
bonding and solvation, thus generating protein coronas with environment-specific 
stability and characteristics. In human blood, a protein corona normally consists of 
serum albumin, immunoglobulins, fibrinogen and apolipoproteins (Ge et al., 2011; 
Hellstrand et al., 2009; Jansch et al., 2012). For some nanoformulations, more 
abundant proteins such as albumin and fibrinogen may initially aspecifically bind to 
nanoformulations and subsequently can be replaced by other proteins having higher 
binding affinity (Saptarshi et al., 2013). Therefore, the distribution of these 
nanoformulations is less simple to determine theoretically and further research is 
needed in this area. 
Nanoformulations of a certain size and composition are able to diffuse in tissues 
through well characterised processes, such as the enhanced permeability and 
retention (EPR) effect, while some nanoformulations might accumulate in specific 
cell populations, allowing the targeting of specific organs. The EPR effect is the 
mechanism by which high-molecular-weight drugs, pro-drugs and nanoparticles tend 
to accumulate in sites of inflammation or cancer, which are tissues with increased 
vascular permeability (Matsumura and Maeda, 1986). Tumour vasculatures have 
large pores, ranging from 100 nm to several hundred nanometers in diameter, as 
compared to normal vessel junctions of 5–10 nm (Hobbs et al., 1998). Consequently, 
nanoformulations can be designed to preferentially penetrate with higher efficiency in 
tumour tissue. As an additional factor, the lymphatic system in tumours might be 
impaired, increasing the retention of macromolecules and nanoformulations (Maeda 
et al., 2000). In some cases this targeting method is not very effective, and the size-
dependency, slow time frame, and variability from tumour to tumour limit treatment 
effectiveness (Iyer et al., 2006; Maeda et al., 2000) 
Complex biological barriers can protect organs from exogenous compounds and the 
blood brain barrier (BBB) represents an obstacle for many therapeutic agents 
(Varatharajan and Thomas, 2009). Multiple cell populations comprising of endothelial 
cells, microglial cells, pericytes and astrocytes are present in the BBB which contain 
extremely restrictive tight junctions and efflux mechanisms, limiting the permeation of 
most drugs (Begley, 2004). Transport through the BBB is restricted to small lipophilic 
molecules and nutrients that are carried by specific transporters. One of the most 
important mechanisms regulating diffusion of nanoformulations into the brain is 
endocytosis by brain capillary endothelial cells. Recent studies have correlated 
particle properties with nanoformulation entry pathways and processing in the human 
BBB endothelial barrier, indicating that uncoated nano-particles have limited 
penetration through the BBB and that surface modification can influence the 
efficiency and mechanisms of endocytosis (Georgieva et al., 2011; Lee et al., 2000). 
In many cases low penetration of nanoformulations into tissues can be a major 
barrier for the treatment of diseases. The use of ligands to enhance this process of 
uptake into tissue represents a promising solution (Ruoslahti, 2012). Tumour-
penetrating peptides have been utilized which can activate bulk tissue-specific 
transport pathways, targeting receptors present in the tumour vasculature such as 
annexin1 (Hatakeyama et al., 2011; Oh et al., 2004), plectin-1, (Kelly et al., 2008) 
and neuropilin-1 (Teesalu et al., 2009). 
The migration of monocytes in numerous tissues and sites of inflammation, infection, 
and tissue degeneration provides a unique mechanism to improve drug delivery 
(Lameijer et al., 2013; Murphy et al., 1975). Indeed, monocytes and macrophages 
have a central role in the pathogenesis of several diseases such as HIV (Crowe et 
al., 2003), tuberculosis (Philips and Ernst, 2012), leishmaniasis (Farah et al., 1975), 
cancer (Biswas and Mantovani, 2010), diabetes (Cnop et al., 2005), inflammatory 
bowel disease (Heinsbroek and Gordon, 2009), rheumatoid arthritis (Szekanecz and 
Koch, 2007) and chronic obstructive pulmonary disease (Barnes, 2004), making 
these cells desirable drug targets in themselves. Nanoformulations can be 
engineered, controlling size and surface charge, to allow for their active uptake by 
monocytes and macrophages through phagocytosis. Monocytes and macrophages 
are characterised by a broad variety of receptors, which can be actively targeted 
using nanoformulations combined with specific ligands (Kelly et al., 2011).  
 
Elimination and Clearance 
A multitude of processes can regulate the clearance of nanoformulations, from 
chemical and enzymatic degradation to renal and biliary elimination. 
Nanoformulations may undergo degradation in penetrated tissues or circulating 
blood, gradually releasing their content. Degradation kinetics is an important variable 
that controls drug release and complicates the design of optimal drug delivery 
systems with predictable drug release properties (Mohammad and Reineke, 2013). 
The immune system is responsible for removing foreign objects from the body, 
including not only pathogens but also any material it may be in contact with, 
including nanoformulations. It is of fundamental importance to achieve a thorough 
understanding of the way nanoformulations interact with immune cells and all related 
consequences. Macrophages in the liver are a major pool of the total number of 
macrophages in the body. Around 8.6 ± 1.4 x 105 Kupffer cells are present in one 
gram of human liver tissue (Friedman et al., 1992) and this cell population possesses 
numerous receptors for selective phagocytosis of opsonized particles (receptors for 
complement proteins and for the Fc part of IgG). Small inorganic nanoparticles are 
effectively phagocytosed by Kupffer cells which can have a central role in the 
generation of active oxygen species, tumor necrosis factor-α and nitric oxide, 
resulting in liver injury (Chen et al., 2013; Sadauskas et al., 2007). Cells with 
phagocytic activity are also present in the spleen which is another major site for 
nanoformulation elimination (Vyas and Malaiya, 1989). Nanoformulations containing 
polyethylene glycol (PEG) are characterised by prolonged presence in the systemic 
circulation by inhibiting receptor interactions and thus preventing phagocytosis by the 
mononuclear phagocytic system (Bazile et al., 1995). Renal clearance is one of the 
most important mechanisms mediating nanoformulation excretion. The glomerular 
endothelium is characterised by fenestrations of 50-100 nm, with capillaries having a 
basement membrane (300nm thickness) as well as podocytes with phagocytic 
functionality.  
 




Types of nanoformulations and pharmacokinetic challenges 
The distribution of nanoformulations is influenced by multiple factors, including the 
nanoformulation physicochemical properties and composition, route of administration 
and characteristics of the individual to which the nanoformulations are administered. 
The most promising types of nanoformulations used for drug delivery are: inorganic 
nanoparticles, solid drug nanoparticles (SDN), solid lipid nanoparticles (SLNs), 
nanoemulsion (NEs), liposomes, polymeric nanoparticles and dendrimers (Figure 2). 
Hybrid nanoformulations, which contain elements of more than one nanoformulation 
class, are also possible, thus complicating classification. 
A common goal of nanomedicine research is to increase the bioavailability of drugs 
and to manipulate movement of drug to target sites in the body. Table 1 gives 
examples of improvements in drug PK seen in selected nanoformulation studies. In 
this section we will review some interesting applications used for the different 
nanodelivery systems and the physiological and molecular processes regulating their 
absorption, distribution, metabolism and elimination. 
 
Inorganic nanoparticles 
A wide variety of inorganic oxides have been used to create nanoparticles, such as 
gold (Thakor et al., 2011), silver (Ong et al., 2013; Zhang et al., 2013), silica (Wu et 
al., 2013) and iron (Ittrich et al., 2013). The potential uses of inorganic nanoparticles 
vary greatly and can include molecular diagnostics (Radwan and Azzazy, 2009), 
photoacoustic imaging (Lu et al., 2011), targeted drug delivery (Assifaoui et al., 
2013; Chamundeeswari et al., 2013), photothermal therapy (Huang et al., 2006) and 
nonviral gene-delivery vectors (Sitharaman et al., 2008). A particularly fascinating 
use of iron oxide nanoparticles has been to actively target specific tissues using an 
external magnetic influence (Dilnawaz et al., 2010). The biodistribution, elimination 
and potential toxicity of inorganic nanoparticles vary wildly depending on materials 
used, and have been reviewed previously (Almeida et al., 2011; Bachler et al., 2013; 
Choi et al., 2007; Pelley et al., 2009; Waalkes, 2000). As a paradigm example we 
have focussed here on silver nanoparticles. 
Following i.v. injection, silver nanoparticles are rapidly removed from the blood and 
widely distributed to organs, in particular the liver, lungs and spleen (Lankveld et al., 
2010). The size of the silver nanoparticles can influence distribution, with particles 
larger than 20 nm being more readily accumulated in tissue. The ionic silver in the 
body is changed to silver sulphide via mercaptan interaction, and is also metabolised 
to silver-glutathione for biliary secretion (Ballatori and Clarkson, 1985). The major 
elimination route of intact 33 nm silver nanoparticles was found to be the kidneys via 
tubular secretion (Malfatti et al., 2012). A PBPK model has been created which 
predicts the exposure of silver nanoparticles in both rats and humans (Bachler et al., 
2013). 
 
Solid drug nanoparticles (SDNs) 
SDNs are lipid-free nanoparticles which are used to improve the oral bioavailability 
and exposure of poorly water-soluble drugs (Chan, 2011; Tanaka et al., 2012). 
Constituents include drug and stabiliser, and SDNs are produced using a “top-down” 
(high pressure homogenisation and wet milling) or bottom-up (solvent evaporation 
and precipitation) approach (Zhang et al., 2011). Our group has developed efavirenz 
SDNs which exhibit around four-fold higher pharmacokinetic exposure after oral 
administration to rodents, compared to free drug (Kreuter, 1994; McDonald et al., 
2013) (Siccardi et al., 2013a). In a separate study, a single s.c. injection of rilpivirine 
SDN resulted in a constant release of around 25 ng/mL for 20 days, providing 
evidence that s.c. injections of antiretroviral SDNs could be used for long-acting 
therapy (Baert et al., 2009). 
It is not fully known whether SDNs remain intact following oral absorption, and 
therefore the relevance of SDN distribution and elimination in vivo is poorly 
understood.  
 
Solid lipid nanoparticles (SLNs) 
SLNs consist of a lipid (or lipids) which is solid at room temperature, an emulsifier 
and water. Lipids utilised include, but are not limited to, triglycerides, partial 
glycerides, fatty acids, steroids and waxes (Mehnert and Mader, 2001). Different 
combinations of lipid and emulsifier can be used to create unique SLN properties, 
such as drug release rate and pH sensitivity, although the effects this has on the 
SLNs in vivo is poorly understood. Due to their lipid core, SLN’s are most suited for 
delivery of highly lipophilic drugs, although enhanced delivery of hydrophilic drugs, 
such as the anti-tubercular drug isoniazid, has been achieved in vivo (Bhandari and 
Kaur, 2013a). The use of SLNs to deliver siRNA and siRNA-drug combinations has 
also been demonstrated (Lobovkina et al., 2011; Yu et al., 2012). 
SLNs have successfully been used to increase the absorption of drugs. Olanzapine-
loaded cationic SLNs showed a 4.3-fold increase in olanzapine exposure (Sood et 
al., 2013) and 2.6-fold increase in tamoxifen exposure (Hashem et al., 2013) 
compared to free drug.  
The in vivo fate of SLNs are determined by several factors, including the inherent 
stability and physicochemical properties of the SLNs, the biological and enzymatic 
surroundings of the administration site, and the distribution process from the 
administration site. Using pulmonary (Videira et al., 2012), subcutaneous 
(Harivardhan Reddy et al., 2005), and oral (Cavalli et al., 2000; Paliwal et al., 2009; 
Zara et al., 2002) dosing strategies, SLNs have been shown to target the lymphatic 
system in vivo.  
An advantage of using SLNs is that formulations are believed to be safe and easily 
cleared from the body. Organic solvent is not required for SLN production, and the 
lipids which are used are usually biodegradable, thus reducing the risk of SLN -
accumulation-associated toxicities. This degradation provides further benefits, as the 
size and choice of lipid influences the elimination rate of SLNs, with longer lipids 
generally outlasting smaller lipids and waxes lasting longer than triglycerides, 
allowing for controlled release of drug. Due to the solid status of SLNs, elimination is 
generally slower than with liquid-lipid-based nanoformulations. 
Interestingly, PEGylated solid lipid particles have an increased clearance rate 
following repeat i.v. or s.c. administration (Zhao et al., 2012a; Zhao et al., 2012b). 
This phenomenon is caused by immune response to PEG and subsequent removal 
of SLNs from the circulation, referred to as the “accelerated blood clearance” (ABC) 




Liquid droplets of less than a 1000 nm dispersed in an immiscible liquid are 
classified as NEs. NEs represent excellent carriers for transport of hydrophobic and 
hydrophilic substances and can find application in intravenous (Ichikawa et al., 
2007), oral (Sun et al., 2012), transdermal (Khurana et al., 2013), nasal (Bahadur 
and Pathak, 2012) and ocular (Badawi et al., 2008) drug delivery. The rate of 
lipolysis and the organ-specific elimination of nanoemulsions are influenced by the 
choice of constituents and route of administration, which allows for a more controlled 
release of drug. Oral administration is the route of choice for chronic therapy and 
NEs can effectively enhance oral bioavailability of small molecules, peptides and 
proteins. The mechanisms through which NEs mediate higher oral absorption are 
improved drug solubilisation, protection from enzymatic and chemical hydrolysis and 
increased permeability due to surfactant-induced membrane fluidity. The 
hydrophobic core of the NEs is an ideal environment for drugs with poor solubility in 
water and the surfactants present in the formulation favour the solubilised state in 
the GI tract. BCS class II compounds (high permeability, low solubility) are ideal 
candidates for NEs and their pharmacokinetics can be greatly enhanced through this 
nanotechnology. Paradigmatic examples of this are represented by drugs such as 
Ramipril, Ezetimibe (Bali et al., 2010) and Anethol trithione (Han et al., 2009) which 
the bioavalability has been increased 2.3, 3 to 4 and 2 to 3 fold, respectively, 
compared to traditional formulations. In a study using Balb/c mice, orally-dosed 
saquinavir in flax-seed oil nanoemulsion was found to have more than two-fold 
increased exposure in brain, compared to free drug (Vyas et al., 2008). 
 
Polymeric nanoparticles 
Polymeric nanoparticles are solid particles typically around 200-800 nm in size which 
can be created using both synthetic and natural polymers. The natural polymers 
used are generally biodegradable and can include as examples gelatine, cellulose, 
chitosan and gluten (Zhang et al., 2007). Synthetic polymers such as polyactides, 
poly(d,l-lactic-co-glycolide) (PLGA) and PEG allow for a high level of degredation 
control. Different polymers are often used in combination, forming copolymers with 
potentially beneficial properties, such as pectin-PLGA (Liu et al., 2004) and alginate–
chitosan-PLGA (Zheng et al., 2004). Polymers can also be blended with or attached 
to other nanoformulation types, such as polymer-liposome complexes used for 
targeted co-delivery of drug and gene to cancer cells (Wang et al., 2010). These 
properties make polymer nanoparticles an extremely versatile tool for improving drug 
delivery.  
Polymeric nanoparticles can be used to increase the bioavailability of drugs and 
other substances, compared to traditional formulations (Morgen et al., 2012). The 
size of polymeric nanoparticle has been shown to influence oral absorption. The 
absorption potential of chitosan nanoparticles of sizes 300 nm to 1000 nm were 
assessed, with 300 nm showing greater permeation in both Caco-2 cells and rat oral 
dose studies (He et al., 2012). Polymer-coated nanoparticles are capable of actively 
targeting tissues such as hepatocytes, lymph nodes and tumours (Muthiah et al., 
2013), therefore allowing for targeted therapy and avoidance of organ-specific 
toxicity. Clearance of polymeric nanoparticles is dependent on several factors, such 
as choice of polymer and co-polymers, polymer size, polymer charge and the 
existence of active tissue targeting. Trends in clearance have been observed, with 
positively charged nanoparticles larger than 100 nm being eliminated predominantly 
via the liver (Alexis et al., 2008). 
Polymeric nanoparticles are capable, both purposefully and inadvertently, of 
affecting the host immunological response. As an example, PEG has been utilised to 
reduce the immune response to nanoformulations by shielding the particle surface 
from recognition (Moghimi, 2002). This technique has only been partly successful, as 
a long term PEG-specific immune response has been observed in subsequent 
studies (Ishida et al., 2007; Wang et al., 2007). Time-dependent immune system 
stimulation by nanoformulations may influence pharmacokinetics, as phagocytosis-
driven increases in nanoformulation clearance would potentially occur. 
 
Dendrimers 
Dendrimers are tree-like, nanostructured polymers that have received significant 
attention as drug delivery systems, due to their well-defined size, tailorable structure, 
and potentially favourable biodistribution (Biricova and Laznickova, 2009). 
Dendrimer-based drug delivery systems can be manufactured to provide theoretically 
almost any size, but are commonly 10–20 nm in diameter and show promise as 
agents for imaging (Kobayashi and Brechbiel, 2004), gene therapy (Dufes et al., 
2005), drug delivery (Svenson, 2009) and biological adhesive (Joshi and Grinstaff, 
2008). 
Due to the near-infinite variety of possible dendrimer structures, an understanding of 
how these structures will relate to ADME/PK is a problematic task. Properties 
specific to each dendrimer, such as size, shape, charge, hydrophobicity and 
hydrodynamic weight, may all potentially alter disposition in vivo, as could 
attachments to the dendrimer structure such as PEG, drugs, RNA or antibodies 
(Kaminskas et al., 2011). Further research is needed to understand these 
relationships to ensure optimum disposition and to avoid toxicity issues. 
 
Liposomes 
Liposomes are spherical vesicles consisting of a phospholipid bilayer. A variety of 
lipids can be utilised, allowing for a degree of control in degredation level. In addition 
to oral dosing, liposomes can be administered in many ways, including intravenously 
(McCaskill et al., 2013), transdermally (Pierre and Dos Santos Miranda Costa, 2011), 
intravitreally (Honda et al., 2013), pulmonary (Chattopadhyay, 2013) 
Encasing drug in liposomes can dramatically increase drug exposure. In a PK study 
using Kunming mice, danorubicin liposomes had a 13-fold higher AUC0-48h compared 
with free drug (Ying et al., 2011). Drug in liposomes often show greater PK variability 
than free drug, which is exacerbated when the clearance rate of the liposomes is low 
(Schell et al., 2013). This could potentially prevent the use of liposomes to deliver 
drugs with a small therapeutic window. 
Liposomes have the potential to radically alter tissue distribution of encapsulated 
drugs, which allows for targeting of tissues, such as the lymphatic system and brain 
(Cai et al., 2011; Lai et al., 2013), but this can also lead to increased toxicity. As an 
example, in a tumour-expressing CD1 mouse study, liposome encapsulation 
increased zoledronic acid 20 to 100-fold in liver, 7-10-fold in tumour and 2-fold in 
bone, which resulted in more than 50-fold increase in drug-associated toxicity in 
animals but no additional inhibition of tumour growth (Shmeeda et al., 2013). 
Liposomes can be combined with synthetic polymers to form lipid-polymer hybrid 
nanoparticles (LPNs), extending their ability to target specific sites in the body 
(Hadinoto et al., 2013). 
The clearance rate of liposome-encased drugs is determined by both drug release 
and destruction of liposomes (uptake of liposomes by phagocyte immune cells, 
aggregration, pH-sensitive breakdown, etc) (Ishida et al., 2002). In a PK study using 
Kunming mice, docetaxel clearance was reduced from 19.9 to 7.5 L/h*kg when 
liposome-encased, resulting in a 81% increase in t1/2 (Zhang et al., 2012). Similarly 
to solid lipid particles, liposomes attached to PEG also show ABC following repeat 
doses (Suzuki et al., 2012). 
 
PBPK and nanotechnology: challenges and limitations 
PBPK requires large amounts of information. 
 
Commonly used blood-to-tissue partition coefficients may not apply to 
nanoformulations. 
The lymphatic system is not routinely included in PBPK models (REF). Considering 
that the lymphatic system has been shown to be integral to the absortion (REF) and 
distribution (REF) of certain nanoformulations, a full inclusion of this system 
 
Unusual “metabolism” of nanoformulations (pH-triggered, phagocytisede etc) and in 
different parts of body to standard drugs (also internal distruibution in cells?). Would 
need integration into PBPK models for comprehensive prediction. 
 
  
The huge number of potential nanoformulation to select for a particular drug/vaccine 
etc. There is perhaps traits within nanoformulation classes (eg SDNs unlikely to 
accumulate in body after absorption etc).  
 
 
A minor alteration in nanoformulation size, shape, charge can potentially have large 
influence of the exposure and effectiveness of an encapsulated or attached drug.  
Optimization of nanoformulation design 
Numerous polymers and materials have been developed for the preparation of 
nanoformulations and the ideal components should be non-toxic, non-immunogenic, 
and should allow for the transport and release of sufficient amount of drug. 
Nanoformulation composition has been correlated with tissue distribution patterns, 
highlighting how the inclusion of specific polymers can have a critical effect on 
nanoformulation distribution. A paradigm example is Poly-ethylene glycol (PEG), 
which can be adsorbed or covalently attached to the surface of nanoformulations. 
PEG has been shown to reduce the interaction between nanoformulations and 
proteins due to its hydrophilicity and repulsion effect, reducing opsonisation, 
complement activation, phagocytosis and clearance mechanisms (Bazile et al., 
1995). Moreover it appears evident that the chain length, shape, and density of PEG 
on the particle surface are important parameters affecting nanoformulation PEG 
stealth activity (Gref et al., 2000). In the study by Gref et al, the ideal molecular 
weight, density and content of PEG were optimised to minimise the amount of 
plasma protein absorbed, thus reducing uptake by polymorphonuclear leukocyte 
(PMN) and human monocyte (THP-1).  
The physiological processes regulating nanoformulation ADME, such as hepatic 
filtration, tissue extravasation, tissue diffusion and kidney excretion, indicate that 
nanoformulation size is a key determining pharmacokinetic factor. A clear example of 
the importance of size is given by a study investigating polystyrene nanoparticles, 
where particle sizes of 50 and 500 nm showed higher levels of agglomeration of the 
larger nanoparticles in the liver (Nagayama et al., 2007). Size and polydispersity can 
substantially affect the distribution of micelles which have a half-life of around 8 
hours with a low hepatic and spleen uptake (Rijcken et al., 2007). Considering 
dendrimers, size has been the best characterised property and it is thought to be a 
determinant predictor of in vivo distribution. Rapid clearance mediated by the kidney 
has been observed for smaller dendrimers (Generation 5 (G5) or smaller, with a 
radius of less than 3.5 nm), with minimal or no renal clearance observed for larger 
dendrimers. Dendrimers of generation G7, characterised by radius above 5nm, 
readily accumulate in the liver and spleen tissue and, consequently, are cleared by 
the RES system and by biliary excretion. (Kobayashi et al., 2001a; Kobayashi et al., 
2001b).  
Characteristics of the nanoformulation surface, such as charge or functional groups, 
can influence the uptake of different cell populations. The effect of surface 
roughness and charge on the cellular uptake of polymeric/silica nanoparticles in 
HeLa cells has been recently investigated, and rough nanoparticles are internalized 
by the cells more slowly and by an unidentified uptake route compared to smooth 
nanoparticles. Moreover, nanoparticles with negative charges are internalised with 
higher efficiency compared to positively charged ones, independent of the surface 
roughness (Schrade et al., 2012). In another study, silica-based fluorescent 
nanoparticles were tested in murine pre-osteoblast cell line, MC3T3-E1 and the 
effect of three surface modified nanoparticles were analysed: positively charged 
(PTMA), negatively charged (OH), and neutrally charged polyethylene glycol (PEG). 
Positively charged PTMA-modified nanoparticles demonstrated the most rapid 
uptake, within 2 hours, while PEG modified and negatively charged OH 
nanoparticles demonstrated slower uptake (Ha et al., 2013). Preferential uptake of 
polystyrene nanoparticles by phagocytic cells has been recently investigated and 
carboxylated nanoparticles were highly phagocyted in macrophages while amino-
functionalized particles had higher uptake in monocytes (Lunov et al., 2011). The 
interaction between gold nanoparticles (with different hydrophobicity, charge density 
and ligand length) and lipid bilayers has been clarified investigating physicochemical 
properties favouring penetration through the bilayer. Hydrophobic and anionic 
nanoparticles did not have any significant interactions with the bilayer and different 
charge densities may induce pore formation or nanoparticle wrapping, resembling 
first stages of endocytosis. Consequently trough the tuning of charge density it can 
be possible to favour the internalization of nanoparticles into cells through different 
mechanisms such as passive translocation, (low charge density) or endocytosis 
(higher charge densities) (McCaskill et al., 2013).  
All the above mentioned factors can interact together, defining a multifactorial 
scenario where multiple nanoformulation properties determine pharmacokinetic 
processes. Consequently, choosing which nanotechnology is the best tool to 
improve the distribution of a defined drug, by the usage of ideal nanoformulation 
characteristics, is a complex problem that unquestionably ought to take into account 
our current knowledge on nanoformulation ADME. This would be possible by 
integrating an exhaustive description of the physicochemical, physiological and 
molecular processes underpinning nanoformulation pharmacokinetics with the 
correlation between nanoformulation characteristics and their distribution.  
A helpful pharmacological tool to inform the design of nanoformulations and thus 
optimise their pharmacokinetics is represented by physiologically based 
pharmacokinetics (PBPK) modelling. This modelling technique has been 
successfully used for traditional formulation in drug developing programs as well as 
simulation of relevant clinical scenarios (Karlsson et al., 2013; Siccardi et al., 2012; 
Siccardi et al., 2013b). PBPK modelling is a bottom up technique which aims to 
simulate drug distribution by combining system data describing a population of 
interest (e.g. demographics, physiology, anatomy and genetics) with in vitro drug 
data (e.g. Caco-2 permeability, protein binding, intrinsic clearance, lipophilicity) 
through a mathematical description of absorption, distribution, metabolism and 
elimination (ADME). This modelling technique gives a complete overview of all the 
physiological and anatomical processes involved in drug distribution, offering the 
opportunity to identify important determinants of pharmacokinetics. For traditional 
formulations, absorption can be simulated considering the dynamic interplay 
between dissolution, passive permeability and the affinity/activity of metabolic 
enzymes and transporters. Drug distribution is simulated by evaluating tissue 
volumes and the diffusion of drugs into tissues, which is influenced by 
physicochemical properties (Poulin and Theil, 2002). Moreover, tissues and organs 
are connected by virtual blood and lymphatic flows. To simulate clearance, in vitro 
stability data can be used and integrated into the model using scaling factors. Inter-
patient variability is observed in all of the above processes, and virtual populations 
can be simulated capturing inter-individual variability by considering anatomical and 
physiological characteristics, and their covariance. The application of PBPK models 
for nanomedicines is in its infancy and characterised by several challenges. 
The first study describing a PBPK model for nanoformulations was published in 
2008, predicting the pharmacokinetics of quantum dots in mouse using whole-body 
PBPK. The authors included a distribution coefficient to simulate the diffusion of 
nanoparticle in tissues based on in vitro data, and could predict animal 
pharmacokinetics with good accuracy (Lin et al., 2008). Subsequently, a PBPK 
model for the simulation of carbon nanoparticles was developed, integrating imaging 
data collected in humans using radioactive nanoparticles (Pery et al., 2009). Silver 
nanoparticle PK has been successfully simulated which considered how the effect of 
size and size-dependent tissue distribution influenced toxicity and health risks. 
Unfortunately experimental data could not be match completely, possibly due to the 
effect of other nanoparticle characteristics, such as surface charge and coating, 
which were not included in the PBPK model (Lankveld et al., 2010). PBPK modelling 
for five poly(lactic-co-glycolic) acid (PLGA) nanoparticle formulations prepared with 
different versions of monomethoxypoly (ethyleneglycol) (mPEG) (PLGA, PLGA-
mPEG256, PLGA-mPEG153, PLGA-mPEG51, PLGA-mPEG34) has been 
generated, investigating the relationship between nanoparticle properties (size, zeta 
potential, and number of PEG molecules per unit surface area) and distribution 
parameters. The multivariate regression in the study generated significant linear 
relationships between nanoparticle properties and distribution parameters. 
Subsequently, this in silico model was successfully utilized to predict the distribution 
of a sixth nanoformulation (PLGA-mPEG 495) in mice (Li et al., 2012).  
Temporal exposure and elimination of 5 gold/dendrimer composite nanodevices 
(CNDs) in mice bearing melanoma was evaluated using a PBPK model (Mager et 
al., 2012). The authors concluded that, since specific binding ligands ware lacking, 
size and charge of nanodevices governed most of their in vivo interactions. A PBPK 
model for ionic silver and nano-encaspulated silver was developed on the basis of 
toxicokinetic data from intravenous studies. The authors validated the model 
structure for both silver forms by reproducing exposure conditions (dermal, oral, and 
inhalation) of in vivo experiments and comparing simulated with real pharmacokinetic 
data for plasma and tissues. Interestingly, in all of the cases examined the model 
could successfully predict the distribution of both ionic silver and 15-150 nm silver 
nanoparticles not coated with PEG. The in silico model was also used to asses 
relevant scenarios of exposure to silver nanoparticles such as dietary intake, use of 
three separate consumer products, and occupational exposure (Bachler et al., 2013). 
The effect of chemical components and nanoformulation properties on the 
distribution of nanoformulations is surely significant, but only partially characterised 
and necessitates future research. Moreover, universal property–distribution 
relationships for all materials are unlikely, unless the effect of specific a 
physicochemical property is extremely predominant. PBPK models can be applied to 
simulate drug and nanoformulation pharmacokinetics not only in humans but in 
different animals, therefore PBPK modelling may be applied in preclinical screening 
of nanoformulation, reducing the number of animals used for experimentations 
(Geenen et al., 2013; Willmann et al., 2010; Wong et al., 2010; Yang et al., 2013). 
Besides describing nanoformulation distribution and pharmacokinetic parameters, 
PBPK modelling can provide quantitative evaluation of the influence of 
nanoformulation properties on their absorption, diffusion and clearance. The 
integration of these property–distribution relationships in PBPK models may have 
extensive benefits in nanomedicine research, giving opportunities for innovative 
development of nanotechnologies. This approach will not only improve our 
understanding of the mechanisms underpinning nanoformulation disposition and 
allow for more rapid and accurate determination of their kinetics, but will also help 
clarify interactions between different nanoformulation properties, identifying 
antagonistic or synergistic effects.  Consequently, the design and development of 
nanoformulations can be informed by this modelling approach to generate novel 
nanoformulations with desirable pharmacokinetics (Figure 3). 
 
IDEAS FOR FUTURE PERSPECTIVES 
Use PBPK models with nanoformulations with well described characteristics, perform 
sensitivity analysis to determine the key physiological and physicochemical 
characteristics controlling 
 
Reduce the reliance on in vivo animal data, which is possibly unreliable for nano. 
 
If animal use unavoidable, then PBPK can be used to bridge extrapolate animal data 
to inform human tox/PK studies. Since standard blood-to-tissue parameters do not 
apply to nanoformulations, non PBPK may not be sufficient. 
 
Create catalogue of nanoformulations with well described characteristics in PBPK 
models, for “selection” when a particular trait is required for a future drug. 
 
PBPK can be combined with PD or tox. 
 
PBPK model of the nanoparticle can be combined with a PBPK model of the 




Figure 1. A selection of issues relating to the administration (green boxes), 
distribution (pink boxes) and elimination (orange boxes) of nanomedicines. 
  
Figure 2. Examples of nanodelivery systems. 
 
  
Figure 3. Flow chart representing an optimization process based on PBPK modelling 
and interactions between the different stages. 
  
Drug Formulations Dose Outcome Reference 
Tamoxifen SLN p.o. ↑156% plasma exposure (Hashem et al., 2013) 
Olanzapine SLN p.o. ↑330% plasma exposure (Sood et al., 2013) 
Isoniazid SLN p.o. ↑516% plasma exposure 
(Bhandari and Kaur, 
2013b) 
Lopinavir SLN p.o. ↑95% plasma exposure (Negi et al., 2013) 
Vincristine Liposome i.v. 
↑66% plasma exposure, no 
increased patient toxicity (Yan et al., 2012) 
Indinavir Liposome p.o. 
200-fold higher exposure in 
lymph, no increased toxicity in 
vivo (Gagne et al., 2002) 
Doxorubicin Liposome p.o. Reduced patient toxicity (O'Brien et al., 2004) 
Efavirenz SDN p.o. ↑301% plasma exposure 
(McDonald et al., 
2013) 
Probucol SDN p.o. ↑127% plasma exposure (Nishino et al., 2012) 
Rosuvastatin Nanoemulsion p.o. ↑145% plasma exposure 
(Balakumar et al., 
2013) 
Chloambucil Nanoemulsion p.o. 
↑91% plasma exposure and >2-
fold increase in tumour growth 
suppression (Ganta et al., 2010) 
Primaquine Nanoemulsion p.o. 
↑28% plasma exposure and 
↑40% liver exposure 
(Singh and Vingkar, 
2008) 
Doxorubicin Dendrimer s.c. 
682-fold and 2.7-fold higher 
lymph exposure than standard 
and liposome formulation, 
respectively (Ryan et al., 2013a) 
Zidovudine Dendrimer i.v. 
↑1320% lymph concentration 
3hrs post-dose (Gajbhiye et al., 2013) 
 
Table 1. Examples of improved drug exposure and tissue distribution achieved in 
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